Implementing Curcumin in Translational Oncology Research.

Area of Science:

• Oncology
• Pharmacology
• Microbiome Research

Background:

• Curcumin demonstrates significant potential in preclinical cancer research, with a growing body of evidence from in vitro and animal studies.
• Clinical studies are increasingly validating curcumin's efficacy, providing a basis for its integration into cancer treatment protocols.
• Challenges remain regarding timely data dissemination and precise formulation disclosure in curcumin clinical trials.

Purpose of the Study:

• To provide a comprehensive overview of current curcumin clinical trial data.
• To present detailed results from studies utilizing specific curcumin formulations.
• To explore curcumin's impact on gut microbiota and metabolic reprogramming in clinical settings.

Main Methods:

• Review of publicly available data from curcumin clinical trials.
• Analysis of reported outcomes for various curcumin formulations.
• Discussion of observed phenomena, including effects on gut microbiota and metabolism.

Main Results:

• Clinical data supports curcumin's potential in oncology, with promising outcomes reported.
• Curcumin formulations show effects on gut microbiota and metabolic pathways.
• Evidence suggests curcumin and its metabolites can exert systemic benefits even at low concentrations.

Conclusions:

• Curcumin holds significant promise for clinical oncology applications.
• Further research is needed to address data reporting and formulation standardization.
• Future clinical studies should investigate the systemic effects of curcumin at varying concentrations, considering its local and systemic actions.